List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Categories
Countries
HIV DRUGS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 102 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 102 pages
- Published: 04-08-2019
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.
Market Summary:
Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report:
- How has the global HIV drugs market performed so far and how will it perform in the coming years?
- What are the key regions in the global HIV drugs market?
- Which are the popular class types in the global HIV drugs market?
- What are the major distribution channels in the global HIV drugs market?
- What are the various stages in the value chain of the global HIV drugs market?
- What are the key driving factors and challenges in the global HIV drugs market?
- What is the structure of the global HIV drugs market and who are the key players?
- What is the degree of competition in the global HIV drugs market?
- How are HIV drugs manufactured?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global HIV Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Price Analysis 5.4 Market Breakup by Drug Class 5.5 Market Breakup by Distribution Channel 5.6 Market Breakup by Region 5.7 Market Forecast 5.8 SWOT Analysis 5.8.1 Overview 5.8.2 Strengths 5.8.3 Weaknesses 5.8.4 Opportunities 5.8.5 Threats 5.9 Value Chain Analysis 5.9.1 Overview 5.9.2 Research and Development 5.9.3 Raw Material Procurement 5.9.4 Manufacturing 5.9.5 Marketing 5.9.6 Distribution 5.9.7 End-Use 5.10 Porters Five Forces Analysis 5.10.1 Overview 5.10.2 Bargaining Power of Buyers 5.10.3 Bargaining Power of Suppliers 5.10.4 Degree of Competition 5.10.5 Threat of New Entrants 5.10.6 Threat of Substitutes 6 Market Breakup by Drug Class 6.1 Nucleoside Reverse Transcriptase Inhibitors 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Multi-Class Combination Products 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Protease Inhibitors 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 HIV Integrase Strand Transfer Inhibitors 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Fusion Inhibitors and Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Retail Pharmacies 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Pharmacies 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Europe 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Asia Pacific 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Middle East and Africa 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Latin America 8.5.1 Market Trends 8.5.2 Market Forecast 9 HIV Drugs Manufacturing Process 9.1 Product Overview 9.2 Raw Material Requirements 9.3 Manufacturing Process 9.4 Key Success and Risk Factors 10 Competitive Landscape 10.1 Market Structure 10.2 Market Breakup by Key Players 10.3 Profiles of Key Players 10.3.1 Boehringer Ingelheim International GmbH 10.3.2 Merck & Co., Inc. 10.3.3 ViiV Healthcare 10.3.4 AbbVie 10.3.5 F. Hoffmann-La Roche Ltd. 10.3.6 Teva Pharmaceutical Industries Ltd. 10.3.7 Bristol-Myers Squibb 10.3.8 Gilead Sciences, Inc. 10.3.9 Johnson & Johnson 10.3.10 Cipla Limited 10.3.11 Daiichi Sankyo 10.3.12 Emcure 10.3.13 Hetero Drugs 10.3.14 Mylan |
Market Breakup by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors and Others
- Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
BINDER EXCIPIENTS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 106 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 106 pages
- Published: 04-08-2019
Binder excipients act as an adhesive to hold or bind granules, powders and other dry ingredients so as to impart necessary mechanical strength to pharmaceutical products. These excipients enable agglomeration of the powder into granules in the process known as granulation and also affect their properties, such as compaction, drug release, flow, solubility and strength. Binder excipients are used during drug or medicine formulations to improve disintegration, bulkiness, bioavailability and dissolution rate of the drug. In addition to this, the excipients play a vital role in bringing additional value to the pharmaceutical products by improving their properties such as absorption and controlled release of the active ingredients. According to the latest report by IMARC Group, titled “Binder Excipients Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global binder excipients market reached a value of US$ 1.2 Billion in 2018.
The growing demand for various pharmaceutical products on account of ageing population and rising cases of chronic diseases acts as the major factor driving the binder excipients market worldwide. The recent patent expiries of a number of drugs is further projected to provide a positive thrust to the demand for binder excipients in generic drug manufacturing. Some of the other factors facilitating the market growth are advancements in nanotechnology, emergence of new excipients and rising demand for functionality excipients. Looking forward, the market value is projected to reach a value of US$ 1.7 Billion by 2024, expanding at a CAGR of 5.3% during 2019-2024.
Market Summary:
Based on type, cellulosic excipients are the most popular product type, holding the majority of the total global market. Other major product types are lactose, polyols, povidones, starch and polysaccharides, and co-processed compressible excipients.
On the basis of application, the market has been segmented as tablets and capsules and solution based. Amongst these, tablets and capsules represent the largest segment of the global binder excipients market.
Region-wise, North America is the leading market, accounting for the majority of the total global market. It is followed by Asia Pacific and Europe. Other major regions include the Middle East and Africa, and Latin America.
The competitive landscape of the global binder excipients market has also been examined with some of the key players being Colorcon, Croda International, EMD Millipore, Dow Chemical, FMC BioPolymer, Fuji Chemical Industry and Ingredion.
This report provides a deep insight into the global binder excipients market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the binder excipients market in any manner.
Key Questions Answered in This Report:
- How has the global binder excipients market performed so far and how will it perform in the coming years?
- What are the key regions in the global binder excipients market?
- Which are the popular product types in the global binder excipients market?
- What are the key application segments in the global binder excipients market?
- What are the various stages in the value chain of the global binder excipients market?
- What are the key driving factors and challenges in the global binder excipients market?
- What is the structure of the global binder excipients market and who are the key players?
- What is the degree of competition in the global binder excipients market?
- How are binder excipients manufactured?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Binder Excipients Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Product Type 5.4 Market Breakup by Application 5.5 Market Breakup by Region 5.6 Market Forecast 5.7 SWOT Analysis 5.7.1 Overview 5.7.2 Strengths 5.7.3 Weaknesses 5.7.4 Opportunities 5.7.5 Threats 5.8 Value Chain Analysis 5.8.1 Overview 5.8.2 Research and Development 5.8.3 Raw Material Procurement 5.8.4 Manufacturing 5.8.5 Distribution 5.8.6 Export 5.8.7 End-Use 5.9 Porters Five Forces Analysis 5.9.1 Overview 5.9.2 Bargaining Power of Buyers 5.9.3 Bargaining Power of Suppliers 5.9.4 Degree of Competition 5.9.5 Threat of New Entrants 5.9.6 Threat of Substitutes 6 Market Breakup by Product Type 6.1 Cellulosics 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Lactose 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Polyols 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Povidones 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Starch and Polysaccharides 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Co-Processed Compressible Excipients 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Application 7.1 Tablets and Capsules 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Solution Based 7.2.1 Market Trends 7.2.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Asia Pacific 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Europe 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Middle East and Africa 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Latin America 8.5.1 Market Trends 8.5.2 Market Forecast 9 Binder Excipients Manufacturing Process 9.1 Product Overview 9.2 Raw Material Requirements 9.3 Manufacturing Process 9.4 Key Success and Risk Factors 10 Competitive Landscape 10.1 Market Structure 10.2 Key Players 10.3 Profiles of Key Players 10.3.1 Colorcon 10.3.2 Croda International 10.3.3 EMD Millipore 10.3.4 Dow Chemical 10.3.5 FMC BioPolymer 10.3.6 Fuji Chemical Industry 10.3.7 Ingredion |
Market Breakup by Product Type
- Cellulosics
- Lactose
- Polyols
- Povidones
- Starch and Polysaccharides
- Co-Processed Compressible Excipients
- Others
Market Breakup by Application
- Tablets and Capsules
- Solution Based
Market Breakup by Region
- North America
- Asia Pacific
- Europe
- Middle East and Africa
- Latin America
MEDICAL CANNABIS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 121 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 121 pages
- Published: 04-08-2019
The global medical cannabis market size was estimated to reach a value of US$ 13.4 Billion in 2018. The market is further expected to reach value of US$ 44.4 Billion by 2024, exhibiting a CAGR of 22.9% during 2019-2024. Cannabis is a psychoactive drug which is derived from the cannabis plant of the Cannabaceae family. It has been used medicinally for several years in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, MS, AIDS, ALS, Alzheimer’s, PTSD, Parkinson’s, Tourette’s, etc. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction. Some of these countries include Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, Italy, Mexico, Spain, United Kingdom, United States, Uruguay, etc.
Global Medical Cannabis Market Drivers:
Cannabis is safer and has less severe side effects in comparison to other treatment options. It also finds usage along with other treatments either to enhance their effect or to combat negative side effects. For instance, cannabis is very effective in reducing nausea and increasing appetite among the chemotherapy patients, making the agonizing treatment more tolerable. Similarly, it is also used in combination with traditional opioid painkillers, which enables patients to significantly reduce the dosage and frequency of opioids, and also imparts greater pain relief.
A steadily rising ageing population has also played an significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits.
Clinical trials, R&D activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
Although expenditure on health products are less susceptible to fluctuations in consumer’s expenditure, the uptake of medical marijuana is liable to changes in disposable income due to its unconventional nature. As a result, we expect increasing disposable incomes to create a positive impact on the demand of medical cannabis.
Breakup by Species:
On the basis of species, the market has been segmented as Indica, Sativa and hybrid. Currently, Indica dominates the market, holding the largest share. It is often used in the treatment of insomnia, relaxing the muscles, relieving body pains, headaches and migraines.
Breakup by Derivatives:
Based on derivatives, the market has been divided into Cannabidiol (CBD), Tetrahydrocannabinol (THC) and others. CBD is majorly used for medical purposes due to its non-psychotic effect and low levels of toxicity, whereas, THC is utilised to reduce the side-effects of AIDS and cancer treatment.
Breakup by Application:
The market has also been divided on the basis of application, wherein, cancer represents the leading category. Other major applications of cannabis include arthritis, migraine, epilepsy, etc.
Breakup by End-Use:
On the basis of end-use, the market has been segregated into the pharmaceutical industry, research and development centers, and others. Currently, the pharmaceutical industry represents the biggest end-user.
Breakup by Route of Administration:
Based on route of administration, the market has been categorized into oral solutions and capsules, smoking, vaporizers, topicals and others. Oral solutions and capsules represent the biggest segment, accounting for the largest market share.
Regional Insights:
On a geographical front, North America enjoys the leading position in the market. Recent legalization of cannabis in North America for both recreational and medical purposes has been a major driver of the market growth. Other key regions include Europe, Asia Pacific, Latin America, and Middle East and Africa.
Competitive Landscape:
The report has also examined the competitive landscape of the market. Some of the major players include:
Canopy Growth Corporation
GW Pharmaceuticals
Aurora Cannabis, Inc.
Aphria Inc.
MedReleaf Corporation
Insys Therapeutics, Inc.
CanniMed Therapeutics, Inc.
Cara Therapeutics, Inc.
United cannabis Corporation
Key Questions Answered in This Report:
- How has the global medical cannabis market performed so far and how will it perform in the coming years?
- What are the key regions in the global medical cannabis market?
- Which are the popular species in the global medical cannabis market?
- What are the key derivatives in the global medical cannabis market?
- What are the various applications of medical cannabis?
- Who are the major end-user industries for medical cannabis?
- What are the major routes of administration in the global medical cannabis market?
- What are the various stages in the value chain of the medical cannabis industry?
- What are the key driving factors and challenges in the global medical cannabis industry?
- What is the structure of the global medical cannabis industry and who are the key players?
- What is the degree of competition in the global medical cannabis market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Medical Cannabis Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Species 5.4 Market Breakup by Derivative 5.5 Market Breakup by Application 5.6 Market Breakup by End-Use 5.7 Market Breakup by Route of Administration 5.8 Market Breakup by Region 5.9 Market Forecast 5.10 SWOT Analysis 5.10.1 Overview 5.10.2 Strengths 5.10.3 Weaknesses 5.10.4 Opportunities 5.10.5 Threats 5.11 Value Chain Analysis 5.11.1 Input Suppliers 5.11.2 Collectors 5.11.3 Manufacturers 5.11.4 Distributors 5.11.5 Exporters 5.11.6 Retailers 5.11.7 End-User 5.12 Porters Five Forces Analysis 5.12.1 Overview 5.12.2 Bargaining Power of Buyers 5.12.3 Bargaining Power of Suppliers 5.12.4 Degree of Competition 5.12.5 Threat of New Entrants 5.12.6 Threat of Substitutes 5.13 Key Success and Risk Factors 6 Market Breakup by Species 6.1 Indica 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Sativa 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Hybrid 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by Derivative 7.1 Cannabidiol (CBD) 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Tetrahydrocannabinol (THC) 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Application 8.1 Cancer 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Arthritis 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Migraine 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Epilepsy 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Others 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by End-Use 9.1 Pharmaceutical Industry 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Research and Development Centres 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Others 9.3.1 Market Trends 9.3.2 Market Forecast 10 Market Breakup by Route of Administration 10.1 Oral Solutions and Capsules 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 Smoking 10.2.1 Market Trends 10.2.2 Market Forecast 10.3 Vaporizers 10.3.1 Market Trends 10.3.2 Market Forecast 10.4 Topicals 10.4.1 Market Trends 10.4.2 Market Forecast 10.5 Others 10.5.1 Market Trends 10.5.2 Market Forecast 11 Market Breakup by Region 11.1 North America 11.1.1 United States 11.1.1.1 Market Trends 11.1.1.2 Market Forecast 11.1.2 Canada 11.1.2.1 Market Trends 11.1.2.2 Market Forecast 11.2 Europe 11.2.1 Germany 11.2.1.1 Market Trends 11.2.1.2 Market Forecast 11.2.2 Italy 11.2.2.1 Market Trends 11.2.2.2 Market Forecast 11.2.3 France 11.2.3.1 Market Trends 11.2.3.2 Market Forecast 11.2.4 Netherlands 11.2.4.1 Market Trends 11.2.4.2 Market Forecast 11.2.5 Spain 11.2.5.1 Market Trends 11.2.5.2 Market Forecast 11.3 Latin America 11.3.1 Market Trends 11.3.2 Market Forecast 11.4 Asia Pacific 11.4.1 Market Trends 11.4.2 Market Forecast 11.5 Middle East and Africa 11.5.1 Market Trends 11.5.2 Market Forecast 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications 12.1 Alzheimer’s Disease 12.2 Autism 12.3 Cancer 12.4 Chronic Pain 12.5 Epilepsy 12.6 Migraine 12.7 Digestive Disorders 12.8 Multiple Sclerosis 12.9 Schizophrenia 12.10 Others 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 14 Key Player Profiles |
Market Breakup by Species
- Indica
- Sativa
- Hybrid
Market Breakup by Derivative
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Market Breakup by Application
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Market Breakup by End-Use
- Pharmaceutical Industry
- Research and Development Centres
- Others
Market Breakup by Route of Administration
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Market Breakup by Region
- North America
- United States
- Canada
- Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Latin America
- Asia Pacific
- Middle East and Africa
JAPAN DIABETES MARKET REPORT: 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 89 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 89 pages
- Published: 04-08-2019
The Japan diabetes market reached a value of more than US$ 4 Billion in 2018, registering a CAGR of 4.4% during 2011-2018. The market is further projected to cross US$ 5 Billion by 2024, growing at a CAGR of 3.8% during 2019-2024. Diabetes refers to a chronic disease in which the ability of a human body to produce and respond to insulin hormone becomes impaired. This results in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. In Japan, a large section of the population is over 60 years, an age when type-2 diabetes becomes more prevalent. Moreover, as the Japanese diet consists of a significant portion of refined carbohydrates, like white rice and noodles, it puts the population at a higher risk of developing and aggravating diabetes.
Japan Diabetes Market Drivers:
With the growing influence of western cuisines, increasing working hours and declining domestic agricultural production, consumers are now relying on processed food products and fast-food like burger, taco, hotdog and pizza. As these food products are high in carbohydrates, sodium and preservatives, their rising consumption has increased the cases of diabetes in the country. The other factors that are contributing to the increasing cases of diabetes include growing obese population and sedentary lifestyles. However, to minimize the prevalence of diabetes in the country, the Government of Japan is undertaking several initiatives. For instance, it is offering health insurance to both the citizens and non-citizens residing for more than a year in Japan through their universal health care system.
Breakup by Segment:
Oral Antidiabetics
Insulin
Currently, insulin represents the dominant segment, accounting for the majority of the total market share. Insulin in Japan is usually taken through pens, pumps, syringes and jet injectors as they offer convenience to the patients. Increasing diagnostic rates and awareness among patients are enabling them to incorporate insulin therapy for treating diabetes.
Competitive Landscape:
The competitive landscape of the market has been analyzed in the report with detailed profiles of key players operative in the industry.
Key Questions Answered in This Report:
- How has the Japan diabetes market performed so far and how will it perform in the coming years?
- Which are the popular segments in the Japan diabetes market?
- What are the various stages in the value chain of the Japan diabetes market?
- What are the key driving factors and challenges in the Japan diabetes market?
- What is the structure of the Japan diabetes market and who are the key players?
- What is the degree of competition in the Japan diabetes market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Diabetes Disease Overview 5.1 What is Diabetes? 5.2 Diabetes Diagnosis and Treatment 5.2.1 Diagnosis 5.2.2 Treatment 5.3 Diabetes Complications 6 Japan Diabetes Epidemiology 6.1 Diabetes Population and Prevalence Rates 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2) 6.3 Population and Prevalence Rates by Region 6.4 Population and Prevalence Rates by Gender 6.5 Population and Prevalence Rates by Age Group 7 Japan Diabetes Market 7.1 Market Overview 7.2 Market Performance 7.3 Market Forecast 7.4 SWOT Analysis 7.4.1 Overview 7.4.2 Strengths 7.4.3 Weaknesses 7.4.4 Opportunities 7.4.5 Threats 7.5 Value Chain Analysis 7.6 Porter’s Five Forces Analysis 7.6.1 Overview 7.6.2 Bargaining Power of Buyers 7.6.3 Bargaining Power of Suppliers 7.6.4 Degree of Competition 7.6.5 Threat of New Entrants 7.6.6 Threat of Substitutes 7.7 Market Breakup by Segment 7.7.1 Japan Oral Antidiabetics Market 7.7.1.1 Historical Market Trends 7.7.1.2 Market Breakup by Class 7.7.1.3 Market Shares of Key Players 7.7.1.4 Market Forecast 7.7.2 Japan Insulin Market 7.7.2.1 Historical Market Trends 7.7.2.2 Market Breakup by Class 7.7.2.3 Market Shares of Key Players 7.7.2.4 Market Forecast 8 Competitive Landscape 8.1 Competitive Structure 8.2 Profiles of Key Players |
Japan Diabetes Epidemiology
Japan Diabetes Market
JAPAN GENERIC DRUG MARKET: INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 98 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 98 pages
- Published: 04-08-2019
Japan represents the world’s eighth biggest market for generic drugs in terms of value. Generic drugs, however, have traditionally enjoyed a relatively lower penetration in Japan compared to other developed markets such as the United States and Europe. Historically, the lower penetration of generic drugs in japan was due to several reasons. These included – the perception of inferior quality of generic drugs, the preference of branded drugs among physicians and patients and the limited profits to be made by physicians from pharmaceutical price differentials by prescribing low priced generics. Generic drugs also remained less popular in Japan because of the lack of generic substitution rights by Japanese pharmacists, slower review times in the drug approval process and difficulties working with major pharmaceutical distributors – many of whom were closely tied to major branded drug manufacturers.
The landscape of the japan generic drug market, however, has changed noticeably over the last decade. The Japanese government has identified growth of the country’s generic drug market as imperative to Japan’s long-term economic health. The Japanese government, recognizing the country’s increasing aging population as well as rising costs of branded drugs has begun instituting healthcare policy changes to cut their expenditures on medical costs. Drug costs account for around a fifth of the country’s total medical expenses and reducing this burden has become a cornerstone of Japan’s health administration policy. Substitution of low-cost generic drugs for innovator products has been identified as a strategy where major savings are possible. Driven by these initiatives, the penetration of generics has grown robustly over the past few years. The government has also made a target towards achieving a generic penetration of 60% by 2018. This is expected to create huge opportunities for both domestic and foreign generic manufacturers in Japan.
The report entitled “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” represents an in-depth analysis on the historical, current and future market trends in the generic drug market in Japan. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of generic drug market in Japan. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the generic drug market in Japan.
Key Questions Answered:
- What are generic drugs? How are they different from branded drugs?
- How has Japan’s generic drug market performed in recent years?
- How have generic drugs performed compared to branded drugs?
- What were the total sales and prescriptions for generic drugs in Japan?
- Who are the key players in the Japanese generic drug market? How have they performed?
- What is the structure of the Japanese generic drug market?
- What is the pricing mechanism of generic drugs in Japan?
- What is the value chain of generic drugs in Japan?
- What are the regulations for generic drugs in Japan?
- How are generic drugs distributed in Japan?
- How are generic drugs manufactured?
- What are the raw material and machinery requirements to manufacture generic drugs?
- What are the drivers and challenges in the Japanese generic drug market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Japan Generic Drug Market – Introduction 4.1 What are Generic Drugs? 4.2 Unbranded and Branded Generic Drugs 4.3 Authorized Generic Drugs 5 Why is the Japanese Generic Drug Market So Lucrative 5.1 Blockbuster Drugs Going Off-Patent 5.2 Rising Healthcare Costs Coupled with an Increasing Ageing Population 5.3 Japan Has One of the Lowest Penetration of Generics 5.4 Incentives for Dispensing Generics 5.5 Significant Savings for Payers and Providers 5.6 Biosimilars 6 Global Generic Drug Market 6.1 Market Performance 6.1.1 Value Trends 6.1.2 Volume Trends 6.2 Market Breakup by Country 6.2.1 Market Breakup by Volume 6.2.2 Market Breakup by Value 6.3 Market Forecast 6.4 Most Prescribed Generic and Branded Drugs 7 Japan Generic Drug Market 7.1 Japan Pharmaceutical Market Performance 7.1.1 Value Trends 7.1.2 Volume Trends 7.1.3 Market Breakup by Type 7.1.4 Market Forecast 7.2 Japan Generic Drug Market Performance 7.2.1 Value Trends 7.2.2 Volume Trends 7.2.3 Market Forecast 8 SWOT Analysis 8.1 Overview 8.2 Strength 8.3 Weakness 8.4 Opportunities 8.5 Threats 9 Pricing Mechanism and Profit Margins at Various Levels of Supply Chain 10 Porter’s Five Forces Analysis 10.1 Overview 10.2 Bargaining Power of Buyers 10.3 Bargaining Power of Suppliers 10.4 Degree of Competition 10.5 Threat of New Entrants 10.6 Threat of Substitutes 11 Japan Generic Drug Market- Competitive Landscape 11.1 Japan Generic Drug Market – Competitive Structure 11.2 Japan Generic Drug Market – Breakup by Key Players 11.3 Japan Generic Drug Market – Breakup by Distribution Channel 12 Japan Generic Drug Market- Value Chain Analysis 12.1 Research and Development 12.2 Manufacturing 12.3 Marketing 12.4 Distribution 13 Regulations in Japan Generics Industry 13.1 Approval Pathway of a Generic Drug in Japan 13.1.1 Master File Scheme for Active Ingredients 13.1.2 Equivalency Review 13.1.3 Conformity Audit 13.2 Certifications 13.2.1 MAH (Market Authorization Holder) License for Product Approval 13.2.2 FMA (Foreign Manufacturer Accredited) Certification for Product Approval 13.2.3 DMF (Drug Master File) Registration 13.2.4 GMP (Good Manufacturing Practices) Certification 13.2.5 Manufacturer’s License 14 Japan Generic Drug Market: Key Success Factors 15 Japan Generic Drug Market: Road Blocks 16 Requirements for Setting up a Generic Drug Manufacturing Plant 16.1 Manufacturing Process 16.2 Raw Material Requirements 16.3 Raw Material Pictures 16.4 Land and Construction Requirements 16.5 Machinery and Infrastructure Requirements 16.6 Machinery Pictures 16.7 Plant Layout 16.8 Packaging Requirements 16.9 Utility Requirements 16.10 Manpower Requirements 17 Japan Generic Drug Market – Key Company Profiles |
Global Generic Drug Market
Japan Generic Drug Market
DNA SEQUENCING PRODUCTS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 112 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 112 pages
- Published: 04-08-2019
The global DNA sequencing products market was worth around US$ 4 Billion in 2018, registering a CAGR of 15.8% during 2011-2018. The market is further projected to cross US$ 9 Billion by 2024, growing at a CAGR of 15.2% during 2019-2024. DNA sequencing is the process used for calculating the precise sequence of the four nucleotide bases within a DNA molecule, namely, cytosine, adenine, thymine and guanine. It plays an important role in mapping out the human genome as well as helps in various applied research applications. In line with this, DNA sequencing products are gaining popularity in the pharmaceutical industry as they assist researchers in understanding complex diseases and, in turn, develop personalised medicines for patients. Additionally, DNA profiling has become an integral part of forensic science as these profiles enable investigators to identify and distinguish multiple samples from a pool of DNA.
Global DNA Sequencing Products Market Drivers:
Genome mapping and sequencing of microorganisms have enabled agriculturists to use them for crops and food plants. Over the past few years, specific genes of bacteria have been used in food plants to improve their resistance against insects and pests which has increased their productivity and nutritional value. In addition to this, genomes of several domesticated livestock animals, such as chicken, pig, cow, sheep, and horse, have also been partially or completely sequenced and proven to be useful in the production of livestock with enhanced quality of meat and milk.
The role of DNA sequencing in the in-vitro diagnostics market, particularly for point-of-care diagnostics, is expected to gain momentum. DNA sequencing enables the development of precision medicine in order to offer specific treatments or therapies to patients. It also provides various platforms that enable genetic sequencing and analysis of DNA data at the point-of-care with high accuracy and rapid diagnosis.
Researchers and instrument developers have produced an array of DNA sequencing technologies which offer faster sequencing with higher accuracy at lower costs. For instance, one of the primary market players in the field, Illumina, has launched a system that consists of 10 ultra-high-throughput sequencers and can sequence about 18,000 human genomes per year.
Researchers are now using innovative technologies for genome mapping that take lesser time for completion. Other than this, the reduction in sequencing costs has led many companies to invest in R&D activities and offer cost-effective solutions such as whole genome sequencing, de novo sequencing and specific disease diagnosis.
Breakup by Product Type:
On the basis of the product type, the market has been segmented into consumables and reagents, and equipments. Currently, consumables and reagents represent the largest segment as they generate a higher return-on-investments.
Breakup by Application:
DNA sequencing products find applications across various sectors including biomarkers, diagnostics, reproductive health, personalised medicine and forensics. Amongst these, biomarkers are the most popular application segment of DNA sequencing products as they help in predicting treatment outcomes.
Breakup by End-Use:
Based on the end-use, the market has been segregated into academic and government research institutes, pharmaceutical and biotechnology companies, and hospitals and clinics. At present, DNA sequencing is majorly being used in academic and government research institutes owing to the presence of a large number of research and development projects which involve the practical implementation of data analysis and next-generation sequencing.
Regional Insights:
On a geographical front, North America accounts for the majority of the total global DNA sequencing products market. This can be accredited to the growing geriatric population, prevalence of several chronic diseases and presence of prominent drug manufacturers in the region. North America is followed by Europe, Asia Pacific, Latin America, and Middle East and Africa.
Competitive Landscape:
The nature of the market is fragmented with the presence of numerous small and large manufacturers who compete in terms of prices and quality. Some of the leading players operating in the market are:
Illumina Inc.
Thermo Fisher Scientific Inc.
Roche Diagnostics
Pacific Biosciences of California, Inc.
Beckman Coulter
Key Questions Answered in This Report:
- How has the global DNA sequencing products market performed so far and how will it perform in the coming years?
- What are the key regions in the global DNA sequencing products market?
- Which are the popular product types in the global DNA sequencing products market?
- What are the key application segments in the global DNA sequencing products market?
- What are the major end-use sectors in the global DNA sequencing products market?
- What are the various stages in the value chain of the global DNA sequencing products market?
- What are the key driving factors and challenges in the global DNA sequencing products market?
- What is the structure of the global DNA sequencing products market and who are the key players?
- What is the degree of competition in the global DNA sequencing products market?
- How are DNA sequencing products manufactured?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global DNA Sequencing Products Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Product Type 5.4 Market Breakup by Application 5.5 Market Breakup by End-User 5.6 Market Breakup by Technology 5.7 Market Breakup by Region 5.8 Market Forecast 5.9 SWOT Analysis 5.9.1 Overview 5.9.2 Strengths 5.9.3 Weaknesses 5.9.4 Opportunities 5.9.5 Threats 5.10 Value Chain Analysis 5.10.1 Research and Development 5.10.2 Raw Material Procurement 5.10.3 Manufacturing 5.10.4 Distribution 5.10.5 End-Use 5.11 Porters Five Forces Analysis 5.11.1 Overview 5.11.2 Bargaining Power of Buyers 5.11.3 Bargaining Power of Suppliers 5.11.4 Degree of Competition 5.11.5 Threat of New Entrants 5.11.6 Threat of Substitutes 6 Market Breakup by Product Type 6.1 Consumables and Reagents 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Equipments 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Applications 7.1 Biomarkers 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Diagnostics 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Reproductive Health 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Forensics 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Personalized Medicine 7.5.1 Market Trends 7.5.2 Market Forecast 7.6 Others 7.6.1 Market Trends 7.6.2 Market Forecast 8 Market Breakup by End-User 8.1 Academic and Government Research Institutes 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Pharmaceutical and Biotechnology Companies 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Hospitals and Clinics 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Europe 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Asia Pacific 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Latin America 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Forecast 10 Competitive Landscape 10.1 Market Structure 10.2 Market Breakup by Key Players 10.3 Profiles of Key Players 10.3.1 Illumina Inc 10.3.1.1 Company Overview 10.3.1.2 Description 10.3.1.3 Product Portfolio 10.3.1.4 Financials 10.3.1.5 SWOT Analysis 10.3.2 Thermo Fisher Scientific Inc. 10.3.2.1 Company Overview 10.3.2.2 Description 10.3.2.3 Product Portfolio 10.3.2.4 Financials 10.3.2.5 SWOT Analysis 10.3.3 Roche Diagnostics 10.3.3.1 Company Overview 10.3.3.2 Description 10.3.3.3 Product Portfolio 10.3.3.4 Financials 10.3.3.5 SWOT Analysis 10.3.4 Pacific Biosciences of California, Inc. 10.3.4.1 Company Overview 10.3.4.2 Description 10.3.4.3 Product Portfolio 10.3.4.4 Financials 10.3.4.5 SWOT Analysis 10.3.5 Beckman Coulter 10.3.5.1 Company Overview 10.3.5.2 Description 10.3.5.3 Product Portfolio 10.3.5.4 Financials 10.3.5.5 SWOT Analysis |
Market Breakup by Product Type
- Consumables and Reagents
- Equipments
Market Breakup by Applications
- Biomarkers
- Diagnostics
- Reproductive Health
- Forensics
- Personalized Medicine
- Others
Market Breakup by End-User
- Academic and Government Research Institutes
- Pharmaceutical and Biotechnology Companies
- Hospitals and Clinics
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa